{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:12:22Z","timestamp":1762506742670},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.medcli.2015.12.003","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T06:00:55Z","timestamp":1453788055000},"page":"460-464","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Eliminaci\u00f3n renal de glucosa como tratamiento de la diabetes: de un antiguo m\u00e9todo diagn\u00f3stico a una nueva forma de tratamiento"],"prefix":"10.1016","volume":"146","author":[{"given":"Bel\u00e9n","family":"Dalama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betina","family":"Biagetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2015.12.003_bib0185","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev."},{"key":"10.1016\/j.medcli.2015.12.003_bib0190","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2015.12.003_bib0195","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.medcli.2015.12.003_bib0200","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.medcli.2015.12.003_bib0205","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.12327","article-title":"Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin","volume":"16","author":"Nauck","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.medcli.2015.12.003_bib0210","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2015.12.003_bib0215","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.medcli.2015.12.003_bib0220","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"37","author":"Jabbour","year":"2014","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2015.12.003_bib0225","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dc14-1142","article-title":"Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2015.12.003_bib0230","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.medcli.2015.12.003_bib0235","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"H\u00e4ring","year":"2014","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2015.12.003_bib0240","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2015.12.003_bib0245","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.medcli.2015.12.003_bib0250","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.medcli.2015.12.003_bib0255","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.medcli.2015.12.003_bib0260","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40265-014-0225-5","article-title":"Canagliflozin: A review of its use in patients with type 2 diabetes mellitus","volume":"74","author":"Plosker","year":"2014","journal-title":"Drugs."},{"key":"10.1016\/j.medcli.2015.12.003_bib0265","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2013.850066","article-title":"Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study","volume":"30","author":"Stenl\u00f6f","year":"2014","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.medcli.2015.12.003_bib0270","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.medcli.2015.12.003_bib0275","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.medcli.2015.12.003_bib0280","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial","volume":"56","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia."},{"key":"10.1016\/j.medcli.2015.12.003_bib0285","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.medcli.2015.12.003_bib0290","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2015.12.003_bib0295","first-page":"72","article-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial","volume":"41","author":"Bode","year":"2013","journal-title":"Hosp Pract 1995."},{"key":"10.1016\/j.medcli.2015.12.003_bib0300","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","volume":"38","author":"Neal","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2015.12.003_bib0305","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.medcli.2015.12.003_bib0310","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000364909","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy","volume":"40","author":"Yamout","year":"2014","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.medcli.2015.12.003_bib0315","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2015.12.003_bib0320","first-page":"1","article-title":"SGLT2 inhibition: Efficacy and safety in type 2 diabetes treatment","volume":"29","author":"Scheen","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.medcli.2015.12.003_bib0325","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.medcli.2015.12.003_bib0330","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications."},{"key":"10.1016\/j.medcli.2015.12.003_bib0335","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","article-title":"Urinary tract infections in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications."},{"key":"10.1016\/j.medcli.2015.12.003_bib0340","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.medcli.2015.12.003_bib0345","unstructured":"Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events-ClinicalTrials.gov [consultado 2 Nov 2015]. Disponible en: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01730534"},{"key":"10.1016\/j.medcli.2015.12.003_bib0350","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dom.12261","article-title":"Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes","volume":"16","author":"Dziuba","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.medcli.2015.12.003_bib0355","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) \u2014a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J."},{"key":"10.1016\/j.medcli.2015.12.003_bib0360","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775315006958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775315006958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T23:56:39Z","timestamp":1537055799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775315006958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0025775315006958"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2015.12.003","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eliminaci\u00f3n renal de glucosa como tratamiento de la diabetes: de un antiguo m\u00e9todo diagn\u00f3stico a una nueva forma de tratamiento","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2015.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}